Research graph
References from Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21442
10.3322/caac.21442 · External reference
10.3322/caac.21338
10.3322/caac.21338 · External reference
50 Years of progress in the systemic therapy of non-small cell lung cancer
10.14694/edbook_am.2014.34.177 · 2014 · External reference
10.1038/nrdp.2015.9
10.1038/nrdp.2015.9 · External reference
10.1016/s0140-6736(13)61502-0
10.1016/s0140-6736(13)61502-0 · External reference
10.1007/s40265-014-0182-z
10.1007/s40265-014-0182-z · External reference
Combating acquired resistance to tyrosine kinase inhibitors in lung cancer
10.14694/edbook_am.2015.35.e165 · 2015 · External reference
10.1007/978-1-4614-8778-4_5
10.1007/978-1-4614-8778-4_5 · External reference
10.1097/cad.0000000000000172
10.1097/cad.0000000000000172 · External reference
10.1097/01.ogx.0000472121.21647.38
10.1097/01.ogx.0000472121.21647.38 · External reference
Molecular testing and personalized treatment of lung cancer
10.2174/187446720701150105171219 · 2014 · External reference
Personalized therapy of non-small cell lung Cancer (NSCLC)
10.1007/978-3-319-24932-2_11 · 2016 · External reference
Five critical elements to ensure the precision medicine
10.1007/s10555-015-9555-3 · 2015 · External reference
Epigenetic therapy approaches in non-small cell lung cancer: update and perspectives
10.1080/15592294.2016.1237345 · 2016 · External reference
Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse
10.1113/jphysiol.2013.266411 · 2014 · External reference
Histones and lung cancer: are the histone deacetylases a promising therapeutic target?
10.1007/s00280-013-2223-9 · 2013 · External reference
Histone acetyltransferase PCAF regulates inflammatory molecules in the development of renal injury
10.4161/15592294.2014.990780 · 2015 · External reference
Histone HIST1H1C/H1.2 regulates autophagy in the development of diabetic retinopathy
10.1080/15548627.2017.1293768 · 2017 · External reference
10.1101/cshperspect.a019521
10.1101/cshperspect.a019521 · External reference
10.1016/b978-0-12-405944-3.00009-x
10.1016/b978-0-12-405944-3.00009-x · 2014 · External reference
Structural and functional coordination of DNA and histone methylation
2014 · External reference
10.1016/j.pharmthera.2015.01.002
10.1016/j.pharmthera.2015.01.002 · External reference
Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung Cancer: where are we now and what should we expect?
2018 · External reference
10.1038/ijo.2013.98
10.1038/ijo.2013.98 · External reference
The role of DNA methylation as biomarkers in the clinical management of lung cancer
10.1586/17476348.2013.814397 · 2013 · External reference
10.1038/jhg.2013.66
10.1038/jhg.2013.66 · External reference
10.1111/j.1440-1827.2011.02776.x
10.1111/j.1440-1827.2011.02776.x · External reference
10.1016/j.bbagrm.2014.02.008
10.1016/j.bbagrm.2014.02.008 · External reference
10.1038/nprot.2013.164
10.1038/nprot.2013.164 · External reference
10.1101/gad.2057811
10.1101/gad.2057811 · External reference
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis
10.1182/blood-2011-02-334359 · 2011 · External reference
10.1038/35020506
10.1038/35020506 · External reference
10.1007/s00018-014-1605-4
10.1007/s00018-014-1605-4 · External reference
10.1038/nrm4029
10.1038/nrm4029 · External reference
H3K27 methylation: a focal point of epigenetic deregulation in Cancer
10.1016/bs.acr.2016.05.001 · 2016 · External reference
10.1016/j.ceb.2015.10.003
10.1016/j.ceb.2015.10.003 · External reference
10.4155/fmc-2016-0071
10.4155/fmc-2016-0071 · External reference
10.1007/s00412-015-0570-5
10.1007/s00412-015-0570-5 · External reference
10.1016/j.mrrev.2016.03.005
10.1016/j.mrrev.2016.03.005 · External reference
10.1146/annurev.biophys.34.040204.144452
10.1146/annurev.biophys.34.040204.144452 · External reference
SET domain proteins modulate chromatin domains in eu- and heterochromatin
10.1007/s000180050127 · 1998 · External reference
SET domain protein lysine methyltransferases: structure, specificity and catalysis
10.1007/s00018-006-6274-5 · 2006 · External reference
The active site of the SET domain is constructed on a knot
2002 · External reference
10.1016/j.molcel.2004.06.020
10.1016/j.molcel.2004.06.020 · External reference
Deregulation of H3K27 methylation in cancer
10.1038/ng0210-100 · 2010 · External reference
10.1093/jmcb/mjx027
10.1093/jmcb/mjx027 · External reference
10.1038/nature01075
10.1038/nature01075 · External reference
10.1073/pnas.1933744100
10.1073/pnas.1933744100 · External reference
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas
2005 · External reference
Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics
10.1007/s12094-012-0897-9 · 2013 · External reference
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer
10.1038/srep01911 · 2013 · External reference
Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy
10.1016/j.lungcan.2014.09.010 · 2014 · External reference
EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer
10.1016/j.canlet.2015.01.031 · 2015 · External reference
10.1158/1078-0432.ccr-13-1916
10.1158/1078-0432.ccr-13-1916 · External reference
10.1371/journal.pone.0071670
10.1371/journal.pone.0071670 · External reference
EZH2 promotes progression of small cell lung cancer by suppressing the TGF-beta-Smad-ASCL1 pathway
10.1038/celldisc.2015.26 · 2015 · External reference
EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro
2014 · External reference
EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation
10.1097/jto.0b013e318298762f · 2013 · External reference
MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer
10.1159/000343349 · 2013 · External reference
10.1007/s00280-016-2990-1
10.1007/s00280-016-2990-1 · External reference
10.1038/nature14122
10.1038/nature14122 · External reference
10.1242/dev.102681
10.1242/dev.102681 · External reference
Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients
10.1038/srep06036 · 2014 · External reference
10.1016/j.jtho.2016.12.011
10.1016/j.jtho.2016.12.011 · External reference
10.1016/j.cllc.2018.03.005
10.1016/j.cllc.2018.03.005 · External reference
10.1101/gad.275453.115
10.1101/gad.275453.115 · External reference
Histone methyltransferase G9a modulates hepatic insulin signaling via regulating HMGA1
10.1016/j.bbadis.2017.10.037 · 2018 · External reference
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule ep-CAM
10.1158/0008-5472.can-10-0833 · 2010 · External reference
Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control
10.1016/j.taap.2014.08.015 · 2014 · External reference
SATB2 suppresses non-small cell lung cancer invasiveness by G9a
10.1007/s10238-017-0464-3 · 2018 · External reference
10.1038/cddis.2017.65
10.1038/cddis.2017.65 · External reference
10.1016/j.canlet.2016.07.009
10.1016/j.canlet.2016.07.009 · External reference
10.1111/cas.13245
10.1111/cas.13245 · External reference
10.1016/j.canlet.2014.11.024
10.1016/j.canlet.2014.11.024 · External reference
10.1158/0008-5472.can-16-2159
10.1158/0008-5472.can-16-2159 · External reference
10.1158/0008-5472.can-11-3701
10.1158/0008-5472.can-11-3701 · External reference
miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer
10.1016/j.biopha.2016.12.007 · 2017 · External reference
10.1016/j.canlet.2016.12.038
10.1016/j.canlet.2016.12.038 · External reference
High-SETD8 inactivates p53 in neuroblastoma
10.18632/oncoscience.344 · 2017 · External reference
10.1016/j.biochi.2006.07.009
10.1016/j.biochi.2006.07.009 · External reference
10.1016/s0092-8674(03)00114-4
10.1016/s0092-8674(03)00114-4 · External reference
Chromatin silencing protein and pachytene checkpoint regulator Dot1p has a methyltransferase fold
10.1016/s0968-0004(01)01856-4 · 2001 · External reference
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia
10.1182/blood-2015-11-684225 · 2016 · External reference
10.1074/jbc.m111.328138
10.1074/jbc.m111.328138 · External reference
Tri-methylation of H3K79 is decreased in TGF-beta1-induced epithelial-to-mesenchymal transition in lung cancer
10.1186/s13148-017-0380-0 · 2017 · External reference
10.1093/nar/gkt012
10.1093/nar/gkt012 · External reference
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer
10.1038/srep40664 · 2017 · External reference
10.1016/j.cell.2004.12.012
10.1016/j.cell.2004.12.012 · External reference
Unresolved reference
2013 · External reference
10.1016/j.cbpa.2012.09.015
10.1016/j.cbpa.2012.09.015 · External reference
10.1038/nrm3327
10.1038/nrm3327 · External reference
Targeting histone lysine demethylases - progress, challenges, and the future
10.1016/j.bbagrm.2014.05.009 · 2014 · External reference
10.1038/nrg1945
10.1038/nrg1945 · External reference
10.1074/jbc.c700100200
10.1074/jbc.c700100200 · External reference
10.1038/nature04020
10.1038/nature04020 · External reference
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers
10.1002/ijc.25349 · 2011 · External reference
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer
10.1371/journal.pone.0035065 · 2012 · External reference
10.1016/j.ccell.2015.06.002
10.1016/j.ccell.2015.06.002 · External reference
Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer
10.18632/oncotarget.7077 · 2016 · External reference
LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC)
10.1016/j.biopha.2017.08.057 · 2017 · External reference
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells
10.18632/oncotarget.8563 · 2016 · External reference
LSD1 modulates the non-canonical integrin beta3 signaling pathway in non-small cell lung carcinoma cells
10.1038/s41598-017-09554-x · 2017 · External reference
10.1038/nchembio863
10.1038/nchembio863 · External reference
10.1146/annurev.biochem.78.070907.103946
10.1146/annurev.biochem.78.070907.103946 · External reference
10.1172/jci68642
10.1172/jci68642 · External reference
10.1074/jbc.m113.521625
10.1074/jbc.m113.521625 · External reference
Discovery of a highly selective cell-active inhibitor of the histone lysine demethylases KDM2/7
10.1002/anie.201706788 · 2017 · External reference
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene
2012 · External reference
JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells
10.1007/s13277-016-4999-9 · 2016 · External reference
10.3892/ol.2017.5949
10.3892/ol.2017.5949 · External reference
10.1038/onc.2016.174
10.1038/onc.2016.174 · External reference
10.1158/0008-5472.can-12-4300
10.1158/0008-5472.can-12-4300 · External reference
10.1126/science.1125162
10.1126/science.1125162 · External reference
10.1016/j.cancergen.2014.11.001
10.1016/j.cancergen.2014.11.001 · External reference
KDM4A, KDM4B and KDM4C in non-small cell lung cancer
2015 · External reference
10.1016/j.cell.2010.02.027
10.1016/j.cell.2010.02.027 · External reference
10.1158/0008-5472.can-12-3165
10.1158/0008-5472.can-12-3165 · External reference
Integrin, a transmembrane glycoprotein complex mediating cell-substratum adhesion
10.1242/jcs.1987.supplement_8.13 · 1987 · External reference
10.1146/annurev.cb.03.110187.001143
10.1146/annurev.cb.03.110187.001143 · External reference
10.18632/oncotarget.9539
10.18632/oncotarget.9539 · External reference
10.1016/j.bbrc.2017.07.048
10.1016/j.bbrc.2017.07.048 · External reference
Impact of H3K27 demethylase inhibitor GSKJ4 on NSCLC cells alone and in combination with metformin
10.21873/anticanres.11198 · 2016 · External reference
In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis
2018 · External reference
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
2017 · External reference
10.1016/j.celrep.2017.09.078
10.1016/j.celrep.2017.09.078 · External reference
10.1038/nature13605
10.1038/nature13605 · External reference
10.1042/bst20130003
10.1042/bst20130003 · External reference
10.1016/j.febslet.2010.11.010
10.1016/j.febslet.2010.11.010 · External reference
S-adenosylmethionine: protein-arginine methyltransferase. Purification and mechanism of the enzyme
10.1021/bi00620a013 · 1977 · External reference
10.1016/s1097-2765(03)00224-7
10.1016/s1097-2765(03)00224-7 · External reference
10.4331/wjbc.v5.i2.115
10.4331/wjbc.v5.i2.115 · External reference
10.1074/jbc.m109984200
10.1074/jbc.m109984200 · External reference
Dysregulation of PRMT1 and PRMT6, type I arginine methyltransferases, is involved in various types of human cancers
10.1002/ijc.25366 · 2011 · External reference
CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features
10.1016/j.biochi.2013.10.021 · 2014 · External reference
Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC
10.1016/j.bbrc.2018.01.069 · 2018 · External reference
10.1073/pnas.1008832107
10.1073/pnas.1008832107 · External reference
10.1007/s13277-013-0789-9
10.1007/s13277-013-0789-9 · External reference
10.1093/nar/gkw808
10.1093/nar/gkw808 · External reference
10.1016/j.cell.2004.08.020
10.1016/j.cell.2004.08.020 · External reference
10.1126/science.1101400
10.1126/science.1101400 · External reference
10.1021/cb6002306 · Admitted local publication
Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation
10.1186/s13075-016-1068-0 · 2016 · External reference
10.3892/or.2016.4780
10.3892/or.2016.4780 · External reference
10.1016/j.ejcb.2015.01.002
10.1016/j.ejcb.2015.01.002 · External reference
10.4161/auto.26308
10.4161/auto.26308 · External reference
Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma
10.1016/j.bbrc.2015.01.068 · 2015 · External reference
Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma
10.18632/oncotarget.15528 · 2017 · External reference
10.1007/s00432-018-2631-7
10.1007/s00432-018-2631-7 · External reference
10.1016/j.yexcr.2017.08.024
10.1016/j.yexcr.2017.08.024 · External reference
GSKJ4, a selective Jumonji H3K27 demethylase inhibitor, effectively targets ovarian Cancer stem cells
2015 · External reference
Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer
10.18632/oncotarget.19100 · 2017 · External reference
Inhibition of the histone H3K27 demethylase UTX enhances tumor cell Radiosensitivity
10.1158/1535-7163.mct-17-1053 · 2018 · External reference
10.1016/j.blre.2016.02.001
10.1016/j.blre.2016.02.001 · External reference
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells
10.1124/jpet.114.214577 · 2014 · External reference
10.1038/aps.2013.161
10.1038/aps.2013.161 · External reference
10.1158/2159-8290.cd-16-0800
10.1158/2159-8290.cd-16-0800 · External reference
Discovery and optimization of Tetramethylpiperidinyl Benzamides as inhibitors of EZH2
10.1021/ml400494b · 2014 · External reference
10.1016/j.chembiol.2013.09.013
10.1016/j.chembiol.2013.09.013 · External reference
Targeting EZH2 for cancer therapy: progress and perspective
10.2174/1389203716666150409100233 · 2015 · External reference
10.1101/gad.1524107
10.1101/gad.1524107 · External reference
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells
10.1016/j.lungcan.2012.08.003 · 2012 · External reference
Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus
10.1016/j.ejps.2015.06.021 · 2015 · External reference
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
10.1158/1535-7163.mct-09-0013 · 2009 · External reference
Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens
10.1177/1087057112453765 · 2012 · External reference
10.1038/nature11606
10.1038/nature11606 · External reference
10.1021/cb4008748
10.1021/cb4008748 · External reference
10.1073/pnas.1303800110
10.1073/pnas.1303800110 · External reference
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1 -(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-cell lymphomas
10.1021/acs.jmedchem.6b01315 · 2016 · External reference
Recently discovered EZH2 and EHMT2 (G9a) inhibitors
10.4155/fmc-2016-0096 · 2016 · External reference
10.1111/nyas.12356
10.1111/nyas.12356 · External reference
10.2217/epi.15.84
10.2217/epi.15.84 · External reference
Enhancer of zeste homolog 2 (EZH2) inhibitors
2018 · External reference
10.4155/fmc-2017-0068
10.4155/fmc-2017-0068 · External reference
10.1080/13543784.2016.1175432
10.1080/13543784.2016.1175432 · External reference
10.2174/1568026616666160216154042
10.2174/1568026616666160216154042 · External reference
Altering the course of small cell lung Cancer: targeting Cancer stem cells via LSD1 inhibition
10.1016/j.ccell.2015.06.011 · 2015 · External reference
Abstract 4708: neuroendocrine gene transcript expression is associated with efficacy to lysine-specific demethylase-1 inhibitor RG6016 in small cell lung cancer-derived cell lines
10.1158/1538-7445.am2016-4708 · 2016 · External reference
Antitumor activity of LSD1 inhibitors in lung cancer
10.1080/23723556.2015.1117700 · 2016 · External reference
On your histone mark, SET, methylate!
10.4161/epi.24451 · 2014 · External reference
10.1016/s1097-2765(01)00405-1
10.1016/s1097-2765(01)00405-1 · External reference
Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9: regulation of lysine methyltransferases by physical interaction with their substrates
10.4161/epi.5.8.13278 · 2010 · External reference
DOT1L and H3K79 methylation in transcription and genomic stability
2018 · External reference
Jumonji histone demethylases as emerging therapeutic targets
10.1016/j.phrs.2016.01.026 · 2016 · External reference
Structural chemistry of human SET domain protein methyltransferases
10.2174/1875397301005010085 · 2011 · External reference
Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells
10.1186/1475-2867-8-15 · 2008 · External reference
The histone methyltransferase wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis
10.1002/gcc.22012 · 2013 · External reference
10.1158/1078-0432.ccr-08-0869
10.1158/1078-0432.ccr-08-0869 · External reference
10.1016/j.cancergencyto.2006.01.004
10.1016/j.cancergencyto.2006.01.004 · External reference
